NIAID

Displaying 1 - 6 of 6


VUMC begins study of second COVID-19 vaccine

Vanderbilt University Medical Center has begun recruiting up to 250 participants for a phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.


A “public” target for HIV

Individuals produce unique sets of antibodies in response to HIV infection. That diversity — and the ability of the human immunodeficiency virus to rapidly change its protein coat to avoid detection — has stymied efforts to develop an anti-HIV vaccine.